272 related articles for article (PubMed ID: 25711863)
1. YAP and the drug resistance highway.
Keren-Paz A; Emmanuel R; Samuels Y
Nat Genet; 2015 Mar; 47(3):193-4. PubMed ID: 25711863
[TBL] [Abstract][Full Text] [Related]
2. YAP in MAPK pathway targeted therapy resistance.
Flaherty KT; Wargo JA; Bivona TG
Cell Cycle; 2015; 14(12):1765-6. PubMed ID: 26036142
[No Abstract] [Full Text] [Related]
3. Targeted therapies: Hippo effector YAP1 inhibition—towards a new therapeutic option to overcome drug resistance.
Errico A
Nat Rev Clin Oncol; 2015 Apr; 12(4):190. PubMed ID: 25707626
[No Abstract] [Full Text] [Related]
4. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Lin L; Sabnis AJ; Chan E; Olivas V; Cade L; Pazarentzos E; Asthana S; Neel D; Yan JJ; Lu X; Pham L; Wang MM; Karachaliou N; Cao MG; Manzano JL; Ramirez JL; Torres JM; Buttitta F; Rudin CM; Collisson EA; Algazi A; Robinson E; Osman I; Muñoz-Couselo E; Cortes J; Frederick DT; Cooper ZA; McMahon M; Marchetti A; Rosell R; Flaherty KT; Wargo JA; Bivona TG
Nat Genet; 2015 Mar; 47(3):250-6. PubMed ID: 25665005
[TBL] [Abstract][Full Text] [Related]
5. Somatic Hypermutation of the
Zhang X; Tang JZ; Vergara IA; Zhang Y; Szeto P; Yang L; Mintoff C; Colebatch A; McIntosh L; Mitchell KA; Shaw E; Rizos H; Long GV; Hayward N; McArthur GA; Papenfuss AT; Harvey KF; Shackleton M
Mol Cancer Res; 2019 Jul; 17(7):1435-1449. PubMed ID: 30833299
[TBL] [Abstract][Full Text] [Related]
6. YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer.
Hergovich A
Breast Cancer Res; 2012 Dec; 14(6):326. PubMed ID: 23216692
[TBL] [Abstract][Full Text] [Related]
7. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
Kim MH; Kim J; Hong H; Lee SH; Lee JK; Jung E; Kim J
EMBO J; 2016 Mar; 35(5):462-78. PubMed ID: 26668268
[TBL] [Abstract][Full Text] [Related]
8. OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer.
Yan C; Yang H; Su P; Li X; Li Z; Wang D; Zang Y; Wang T; Liu Z; Bao Z; Dong S; Zhuang T; Zhu J; Ding Y
Oncogene; 2022 Nov; 41(48):5186-5198. PubMed ID: 36271031
[TBL] [Abstract][Full Text] [Related]
9. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia.
Chorzalska A; Kim JF; Roder K; Tepper A; Ahsan N; Rao RSP; Olszewski AJ; Yu X; Terentyev D; Morgan J; Treaba DO; Zhao TC; Liang O; Gruppuso PA; Dubielecka PM
Stem Cells Dev; 2017 May; 26(9):656-677. PubMed ID: 28103766
[TBL] [Abstract][Full Text] [Related]
11. Eradicating tumor drug resistance at its YAP-biomechanical roots.
Zanconato F; Piccolo S
EMBO J; 2016 Mar; 35(5):459-61. PubMed ID: 26711176
[TBL] [Abstract][Full Text] [Related]
12. Stressing out the Hippo/YAP signaling pathway: toward a new role in Schwann cells.
Melfi S; Colciago A; Giannotti G; Bonalume V; Caffino L; Fumagalli F; Magnaghi V
Cell Death Dis; 2015 Oct; 6(10):e1915. PubMed ID: 26469964
[No Abstract] [Full Text] [Related]
13. Hippo signaling dysfunction induces cancer cell addiction to YAP.
Han H; Yang B; Nakaoka HJ; Yang J; Zhao Y; Le Nguyen K; Bishara AT; Mandalia TK; Wang W
Oncogene; 2018 Dec; 37(50):6414-6424. PubMed ID: 30068939
[TBL] [Abstract][Full Text] [Related]
14. Hippo pathway mediates resistance to cytotoxic drugs.
Gujral TS; Kirschner MW
Proc Natl Acad Sci U S A; 2017 May; 114(18):E3729-E3738. PubMed ID: 28416665
[TBL] [Abstract][Full Text] [Related]
15. YAP and TAZ regulate skin wound healing.
Lee MJ; Byun MR; Furutani-Seiki M; Hong JH; Jung HS
J Invest Dermatol; 2014 Feb; 134(2):518-525. PubMed ID: 24108406
[TBL] [Abstract][Full Text] [Related]
16. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
17. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
[TBL] [Abstract][Full Text] [Related]
18. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
[TBL] [Abstract][Full Text] [Related]
19. Survivin: A novel marker and potential therapeutic target for human angiosarcoma.
Tsuneki M; Kinjo T; Mori T; Yoshida A; Kuyama K; Ohira A; Miyagi T; Takahashi K; Kawai A; Chuman H; Yamazaki N; Masuzawa M; Arakawa H
Cancer Sci; 2017 Nov; 108(11):2295-2305. PubMed ID: 28845553
[TBL] [Abstract][Full Text] [Related]
20. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
